JUNS Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Jupiter Neurosciences Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerJUNS

Market Cap9.8M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

Jupiter Neurosciences Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Atogepant in Episodic Migraine (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Atogepant	Episodic Migraine	n/a	Phase 3	Public pipeline row
AVP-786-28	Neurobehavioral Disinhibition	n/a	Phase 2	Public pipeline row
Vilaprisan (BAY1002670)	Uterine Fibroids	n/a	Phase 3	Public pipeline row
Ubrogepant	Migraine, With or Without Aura	n/a	Phase 3	Public pipeline row
Lubiprostone	Opioid-Induced Bowel Dysfunction	n/a	Phase 3	Public pipeline row
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)	Osteoarthritis \| Chronic Pain	n/a	Phase 3	Public pipeline row
Ubrogepant 100 mg	Migraine	n/a	Phase 3	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT00420992	Phase 3	COMPLETED	547	2007-11
NCT00597428	Phase 3	COMPLETED	437	2009-03
NCT02867709	Phase 3	COMPLETED	1686	2018-01-25
NCT02873221	Phase 3	COMPLETED	1254	2018-08-02
NCT03400956	Phase 3	TERMINATED	103	2019-03-23
NCT03700320	Phase 3	COMPLETED	744	2020-05-21
NCT04492020	Phase 3	COMPLETED	518	2022-04-19
NCT03095066	Phase 2	COMPLETED	168	2022-08-22

Scientific Context

literature_publication | Experimental menopause in 3xTg-AD mice exacerbates metabolic, inflammatory, and osteologic phenotypes aligned with Alzheimer's disease pathology.
literature_publication | A new ANMerge-based blood transcriptomic resource to support Alzheimer's disease research.
literature_publication | Amplifying gene expression with RNA-targeted therapeutics.
literature_publication | Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL (TM)).
asset_name | ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)

Want the full JUNS research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.